William Rae

William Rae

Auto-generated profile, based on publicly available information

William Rae

Department of Immunology, MP8, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, Hampshire SO16 6YD, UK

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2020 in Nature
Verified
Journal Article
Closed access
PDF file
JTJames E. D. Thaventhiran
James E. D. Thaventhiran
HAHana Lango Allen
Hana Lango Allen
OBOliver S. Burren
Oliver S. Burren
WRWilliam Rae
William Rae
DGDaniel Greene
Daniel Greene
KSKenneth G. C. Smith
Kenneth G. C. Smith

24 June 2019 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SSSarah Spencer
Sarah Spencer
SBSevgi Köstel Bal
Sevgi Köstel Bal
WEWilliam Egner
William Egner
HAHana Lango Allen
Hana Lango Allen
SRSyed I. Raza
Syed I. Raza
JTJames E.D. Thaventhiran
James E.D. Thaventhiran
IL-6 excess is central to the pathogenesis of multiple inflammatory conditions and is targeted in clinical practice by immunotherapy that blocks the IL-6 receptor encoded by IL6R. We describe two patients with homozygous mutations in IL6R who presented with recurrent infections, abnormal acute-phase responses, elevated IgE, eczema, and eosinophilia. This study identifies a novel primary immunodeficiency, clarifying the contribution of IL-6 to the phenotype of patients with mutations in IL6ST, STAT3, and ZNF341, genes encoding different components of the IL-6 signaling pathway, and alerts us to the potential toxicity of drugs targeting the IL-6R.

16 March 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MMMaria Elena Maccari
Maria Elena Maccari
Hassan AbolhassaniHassan Abolhassani
Hassan Abolhassani
AAAsghar Aghamohammadi
Asghar Aghamohammadi
AAAlessandro Aiuti
Alessandro Aiuti
OAOlga Aleinikova
Olga Aleinikova
SEStephan Ehl
Stephan Ehl
Activated phosphoinositide 3-kinase (PI3K) δ Syndrome (APDS), caused by autosomal dominant mutations in PIK3CD (APDS1) or PIK3R1 (APDS2), is a heterogeneous primary immunodeficiency. While initial cohort-descriptions summarized the spectrum of clinical and immunological manifestations, questions about long-term disease evolution and response to therapy remain. The prospective European Society for Immunodeficiencies (ESID)-APDS registry aims to characterize the disease course, identify outcome predictors, and evaluate treatment responses. So far, 77 patients have been recruited (51 APDS1, 26 APDS2). Analysis of disease evolution in the first 68 patients pinpoints the early occurrence of recurrent respiratory infections followed by chronic lymphoproliferation, gastrointestinal manifestations, and cytopenias. Although most manifestations occur by age 15, adult-onset and asymptomatic courses were documented. Bronchiectasis was observed in 24/40 APDS1 patients who received a CT-scan compared with 4/15 APDS2 patients. By age 20, half of the patients had received at least one immunosuppressant, but 2–3 lines of immunosuppressive therapy were not unusual before age 10. Response to rapamycin was rated by physician visual analog scale as good in 10, moderate in 9, and poor in 7. Lymphoproliferation showed the best response (8 complete, 11 partial, 6 no remission), while bowel inflammation (3 complete, 3 partial, 9 no remission) and cytopenia (3 complete, 2 partial, 9 no remission) responded less well. Hence, non-lymphoproliferative manifestations should be a key target for novel therapies. This report from the ESID-APDS registry provides comprehensive baseline documentation for a growing cohort that will be followed prospectively to establish prognostic factors and identify patients for treatment studies.

1 October 2020 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
TLTiziana Lorenzini
Tiziana Lorenzini
MFManfred Fliegauf
Manfred Fliegauf
NKNils Klammer
Nils Klammer
NFNatalie Frede
Natalie Frede
MPMichele Proietti
Michele Proietti
EZEliska Zlamalova
Eliska Zlamalova

26 July 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
EAEmel Aygören-Pürsün
Emel Aygören-Pürsün
ABAnette Bygum
Anette Bygum
VGVesna Grivcheva-Panovska
Vesna Grivcheva-Panovska
MMMarkus Magerl
Markus Magerl
JGJochen Graff
Jochen Graff
MCMarco Cicardi
Marco Cicardi
Hereditary angioedema is a life-threatening illness caused by mutations in the gene encoding C1 inhibitor (also called C1 esterase inhibitor) that lead to overactivation of the kallikrein–bradykinin cascade. BCX7353 is a potent oral small-molecule inhibitor of plasma kallikrein with a pharmacokinetic and pharmacodynamic profile that may help prevent angioedema attacks.

31 January 2022 in Cell Reports
Verified
Journal Article
Open access
PKPrasanti Kotagiri
Prasanti Kotagiri
FMFederica Mescia
Federica Mescia
WRWilliam M. Rae
William M. Rae
LBLaura Bergamaschi
Laura Bergamaschi
ZTZewen K. Tuong
Zewen K. Tuong
KSKenneth G.C. Smith
Kenneth G.C. Smith
B cells are important in immunity to both severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and vaccination, but B cell receptor (BCR) repertoire development in these contexts has not been compared. We analyze serial samples from 171 SARS-CoV-2-infected individuals and 63 vaccine recipients and find the global BCR repertoire differs between them. Following infection, immunoglobulin (Ig)G1/3 and IgA1 BCRs increase, somatic hypermutation (SHM) decreases, and, in severe disease, IgM and IgA clones are expanded. In contrast, after vaccination, the proportion of IgD/M BCRs increase, SHM is unchanged, and expansion of IgG clones is prominent. VH1-24, which targets the N-terminal domain (NTD) and contributes to neutralization, is expanded post infection except in the most severe disease. Infection generates a broad distribution of SARS-CoV-2-specific clones predicted to target the spike protein, while a more focused response after vaccination mainly targets the spike's receptor-binding domain. Thus, the nature of SARS-CoV-2 exposure differentially affects BCR repertoire development, potentially informing vaccine strategies.